Risdiplam in Presymptomatic Spinal Muscular Atrophy

R Richard S. Finkel (Center for Experimental Neurotherapeutics, Department of Pediatric Medicine, St. Jude Children’s Research Hospital, Memphis, TN) L Laurent Servais (MDUK (Muscular Dystrophy UK) Oxford Neuromuscular Centre and NIHR (National Institute for Health and Care Research) Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom) D Dmitry Vlodavets (Russian Children Neuromuscular Center, Veltischev Clinical Pediatrics and Pediatric Surgery Research Institute of Pirogov Russian National Research Medical University, Moscow) E Edmar Zanoteli (Department of Neurology, Faculdade de Medicina, Universidade de São Paulo, São Paulo) M Maria Mazurkiewicz-Bełdzińska (Department of Developmental Neurology, Chair of Neurology, Medical University of Gdańsk, Gdańsk, Poland) Y Yuh-Jyh Jong A Aledie Navas-Nazario (Division of Pulmonology, Nemours Children’s Health Orlando, Orlando, FL) M Mohammad Al-Muhaizea (Neuroscience Center, King Faisal Specialist Hospital and Research Center–Riyadh, Riyadh, Saudi Arabia) A Alexandra P.Q.C. Araujo (Department of Pediatrics, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro) L Leslie Nelson (Department of Physical Therapy, University of Texas Southwestern Medical Center, Dallas) Y Yi Wang B Birgit Jaber (Pharma Development Safety, F. Hoffmann–La Roche, Basel, Switzerland) K Ksenija Gorni (Product Development Medical Affairs, Neuroscience and Rare Disease, F. Hoffmann–La Roche, Basel, Switzerland) H Heidemarie Kletzl (Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland) L Laura Palfreeman (Roche Products, Welwyn Garden City, United Kingdom) M Michael Rabbia (Genentech, South San Francisco, CA) D Dave Summers (Roche Products, Welwyn Garden City, United Kingdom) E Eleni Gaki (Roche Products, Welwyn Garden City, United Kingdom) K Kathryn R. Wagner (Pharma Development Neurology, F. Hoffmann–La Roche, Basel, Switzerland) P Paulo Fontoura (Product Development Medical Affairs, Neuroscience and Rare Disease, F. Hoffmann–La Roche, Basel, Switzerland) M Michelle A. Farrar (Department of Neurology, Sydney Children’s Hospital Network, Sydney) E Enrico Bertini (Research Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children’s Research Hospital IRCCS, Rome)

Article Details

Volume / Issue Vol. 393, Issue 7
Published August 14, 2025
Pages 671-682
ISSN 0028-4793
Publisher Massachusetts Medical Society

Journal Info

New England Journal of Medicine

Massachusetts Medical Society

ISSN: 0028-4793 Social Sciences

Authors (22)

R

Richard S. Finkel

Center for Experimental Neurotherapeutics, Department of Pediatric Medicine, St. Jude Children’s Research Hospital, Memphis, TN

L

Laurent Servais

MDUK (Muscular Dystrophy UK) Oxford Neuromuscular Centre and NIHR (National Institute for Health and Care Research) Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

D

Dmitry Vlodavets

Russian Children Neuromuscular Center, Veltischev Clinical Pediatrics and Pediatric Surgery Research Institute of Pirogov Russian National Research Medical University, Moscow

E

Edmar Zanoteli

Department of Neurology, Faculdade de Medicina, Universidade de São Paulo, São Paulo

M

Maria Mazurkiewicz-Bełdzińska

Department of Developmental Neurology, Chair of Neurology, Medical University of Gdańsk, Gdańsk, Poland

Y

Yuh-Jyh Jong

A

Aledie Navas-Nazario

Division of Pulmonology, Nemours Children’s Health Orlando, Orlando, FL

M

Mohammad Al-Muhaizea

Neuroscience Center, King Faisal Specialist Hospital and Research Center–Riyadh, Riyadh, Saudi Arabia

A

Alexandra P.Q.C. Araujo

Department of Pediatrics, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro

L

Leslie Nelson

Department of Physical Therapy, University of Texas Southwestern Medical Center, Dallas

Y

Yi Wang

B

Birgit Jaber

Pharma Development Safety, F. Hoffmann–La Roche, Basel, Switzerland

K

Ksenija Gorni

Product Development Medical Affairs, Neuroscience and Rare Disease, F. Hoffmann–La Roche, Basel, Switzerland

H

Heidemarie Kletzl

Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

L

Laura Palfreeman

Roche Products, Welwyn Garden City, United Kingdom

M

Michael Rabbia

Genentech, South San Francisco, CA

D

Dave Summers

Roche Products, Welwyn Garden City, United Kingdom

E

Eleni Gaki

Roche Products, Welwyn Garden City, United Kingdom

K

Kathryn R. Wagner

Pharma Development Neurology, F. Hoffmann–La Roche, Basel, Switzerland

P

Paulo Fontoura

Product Development Medical Affairs, Neuroscience and Rare Disease, F. Hoffmann–La Roche, Basel, Switzerland

M

Michelle A. Farrar

Department of Neurology, Sydney Children’s Hospital Network, Sydney

E

Enrico Bertini

Research Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children’s Research Hospital IRCCS, Rome